Investors' Biggest Worry About GW Pharma Could Be The Biotech's Ace In The Hole
Published: Sep 14, 2017
GW Pharmaceuticals' (NASDAQ:GWPH) stock soared more than 60% last year. So far in 2017, though, shares of the cannabinoid-focused biotech are down rather than up. One possible reason behind GW Pharma's lackluster year-to-date performance is that some investors are worried about the impact of drug-drug interactions with the company's lead candidate Epidiolex.